Thoracic aortic remodeling with endografting after a decade of thoracic endovascular aortic repair experience.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
03 2021
Historique:
received: 10 03 2020
accepted: 22 06 2020
pubmed: 25 7 2020
medline: 28 9 2021
entrez: 25 7 2020
Statut: ppublish

Résumé

Thoracic endovascular aortic repair (TEVAR) results have been studied in short-term time frames. This study aimed to evaluate midterm and long-term outcomes of TEVAR, emphasizing postoperative aortic remodeling and need for reintervention. This is an institutional retrospective review of TEVAR for isolated descending thoracic aortic aneurysms. Data were collected from 2004 to 2018. Primary outcomes studied included aneurysm sac remodeling, freedom from reintervention, and all-cause mortality. Other outcomes studied include endoleak rates, neurologic complication rates, and any overall postoperative complication rates. During the study period, 219 patients underwent TEVAR for descending thoracic aortic aneurysms. The median effect of TEVAR on sac diameter was a 0.7-cm decrease in size (interquartile range, -1.4 to 0.0 cm). During the study period, 80% (n = 147) of patients experienced aneurysm sac regression or stability. Perioperative neurologic complications occurred in 16% (n = 34) of patients. Significant predictors of sac growth were endoleak (odds ratio [OR], 65; P < .001), preoperative carotid-subclavian bypass (OR, 8; P = .003), and graft oversizing <20% (OR, 15; P = .046). Every 1-mm increase in aortic diameter at the proximal TEVAR landing zone led to an increased odds of endoleak (OR, 2; P = .049). Access complications (OR, 8) and subclavian artery coverage (OR, 6) significantly increased the odds of reintervention, whereas every percentage of graft oversizing protected against reintervention (OR, 0.005). Life-table analysis revealed an overall survival of 78% (71%-83%) at median follow-up. At 3 years, survival was 88% (80%-93%) for those with aneurysm sac stability or regression, whereas it was 70% (49%-84%) for those with aneurysm sac growth (P = .0402). Cox proportional hazards model showed that the only protective factor for mortality was percentage oversizing, with every 1% of oversizing having a hazard ratio (HR) of <.001 (P = .032). This was counterbalanced by the fact that patients with graft oversizing >30% had an increased odds of mortality with HR >10 (P = .049). Other significant factors that increased the odds of mortality included endoleak (HR, 3.6; P = .033), diabetes (HR, 4.1; P = .048), age (every 1-year increase in age; HR, 1.2; P = .002), year of surgery (every year subsequent to 2004; HR, 1.3; P = .012), and peripheral artery disease (HR, 5.2; P = .041). The majority of patients (80%) experience sac stability or regression after TEVAR, which offers a clear survival advantage. Endoleaks are predictive of sac growth, conferring increased mortality. Rigorous surveillance is necessary to prevent future aortic events through reintervention.

Identifiants

pubmed: 32707385
pii: S0741-5214(20)31692-X
doi: 10.1016/j.jvs.2020.06.120
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

844-849

Informations de copyright

Copyright © 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Adam Tanious (A)

Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass. Electronic address: atanious@mgh.harvard.edu.

Laura Boitano (L)

Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass.

Lauren Canha (L)

Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass.

Elizabeth L Chou (EL)

Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass.

Linda J Wang (LJ)

Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass.

Christopher Latz (C)

Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass.

Matthew J Eagleton (MJ)

Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass.

Mark F Conrad (MF)

Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, Mass.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH